H.R. 3810 · 118th Congress · House

Drug Origin Transparency Act of 2023

Active· Referred to the Subcommittee on Health.
Introduced
Jun 5, 23
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Drug Origin Transparency Act of 2023 

This bill requires drug manufacturers to report on the suppliers of ingredients used in their products.

Specifically, drug manufacturers must report information relating to the supply chain of their products, including the suppliers of active ingredients and the amount of drugs that are manufactured using those ingredients. Drug manufacturers must also include information about the manufacturers of ingredients on the labels of their products.

Action Timeline

4
  1. JUN 09, 2023Committee

    Referred to the Subcommittee on Health.

  2. JUN 05, 2023IntroReferral

    Introduced in House

  3. JUN 05, 2023IntroReferral

    Introduced in House

  4. JUN 05, 2023IntroReferral

    Referred to the House Committee on Energy and Commerce.

Committees

2

Health Subcommittee

hsif14

Referred: Jun 9, 2023

Active

Energy and Commerce Committee

hsif00

Referred: Jun 5, 2023

Active